Astria Therapeutics Inc. (ATXS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Astria Therapeutics Inc. (ATXS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

7.38

-0.08 (-1.07%)

At close: Jan 14, 2025, 3:59 PM

7.37

-0.20%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	7.25
Market Cap	416.77M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.18
PE Ratio (ttm)	-3.39
Forward PE	n/a
Analyst	Buy

Ask	11
Volume	652,181
Avg. Volume (20D)	293,050
Open	7.52
Previous Close	7.46
Day's Range	7.30 - 7.62
52-Week Range	6.94 - 16.90
Beta	undefined

About ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceutical...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 25, 2015

Employees 59

Stock Exchange NASDAQ

Ticker Symbol ATXS

Website https://www.astriatx.com

Analyst Forecast

According to 5 analyst ratings, the average rating for ATXS stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 265.61% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

5 months ago · Source

+7.48%

Astria Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

News

1 week ago · businesswire.com

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options...

4 weeks ago · zacks.com

Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?

Here is how Astria Therapeutics, Inc. (ATXS) and Abbott (ABT) have performed compared to their sector so far this year.

1 month ago · seekingalpha.com

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Astria Therapeutics, Inc.'s STAR-0215 shows 90-96% reduction in HAE attack frequency, with a twice-a-year dosing regimen, positioning it as a transformative therapy. The company has a strong cash bala...

2 months ago · businesswire.com

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financ...